Immune biomarkers are measurable biological signals which can indicate how a particular mechanism will address a biological effect in a patient, and in turn, predict the likelihood of clinical benefit with I-O therapy.
Driving Precision Medicine for Immuno-Oncology Combinations Through an Innovative Study Design
- In Immuno-Oncology (I-O), targeting complementary immune pathways in the tumor microenvironment may yield more robust anti-tumor responses than targeting a single pathway. Given the vast variety of immune pathways researchers have already identified, the potential number of investigational immunotherapy combinations to study is daunting.
- Improved understanding of immune biomarkers may help researchers select the appropriate investigational treatment – or combination of treatments – for each patient based on disease biology, enabling more personalized approaches in I-O.1
- However, the clinical feasibility and utility of using real-time biomarker data to study I-O combinations in specific patient populations has not been established.
- Powered by translational medicine – research to further the understanding of cancer biology and identify the patients most likely to benefit from I-O treatment – Bristol Myers Squibb is working to quickly implement new insights in clinical trials and explore emerging biomarkers and I-O combinations that may help match the right treatments with the right patients at the right time.
